Differences between in Vivo and in Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obtained from Leukemic Patients
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 28 (3) , 361-372
- https://doi.org/10.1006/bcmd.2002.0526
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Binding of imatinib by α1-acid glycoproteinBlood, 2002
- BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyThe Lancet, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Structural and Signaling Requirements for BCR-ABL-Mediated Transformation and Inhibition of ApoptosisMolecular and Cellular Biology, 1995
- Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogeneCell, 1995